Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO
15 nov. 2021 08h00 HE
|
Recludix Pharma, Inc.
Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underwayNancy Whiting, Pharm.D. -- an industry veteran and one of Fierce Pharma’s Fiercest Women in...